乳腺癌多基因标志（BCMS）已经改变了早期乳腺癌（eBC）患者的管理方式，因为它们提供了预后信息，可以用于选择可能不需要辅助化疗的患者。临床指南对BCMS的使用提出了建议，但目前在临床实践中的使用情况尚不清楚。我们进行了一项两轮Delphi调查，以了解目前的使用情况、特定患者群体的感知效用和BCMS的未满足需求。总共有来自11个欧洲国家、有乳腺癌经验的133名专家参与了调查，其中绝大多数（66.2%）通常使用BCMS或仅在特定情况下（27.1%）使用。我们的结果表明，BCMS主要用于评估复发风险和选择辅助化疗患者；值得注意的是，在选择要使用的化疗类型方面尚未达成共识。此外，在临床实践中，BCMS的推荐和目前使用存在差异，对于某些患者群体的使用缺乏支持性证据。我们的研究表明，需要开展医师教育计划，以确保正确使用和解释BCMS，最终改善eBC患者的管理。©2023年，作者。

Breast cancer multigene signatures (BCMS) have changed how patients with early-stage breast cancer (eBC) are managed, as they provide prognostic information and can be used to select patients who may avoid adjuvant chemotherapy. Clinical guidelines make recommendations on the use of BCMS; however, little is known on the current use of BCMS in clinical practice. We conduct a two-round Delphi survey to enquire about current use and perceived utility for specific patient profiles, and unmet needs of BCMS. Overall, 133 panellists experienced in breast cancer across 11 European countries have participated, most using BCMS either routinely (66.2%) or in selected cases (27.1%). Our results show that BCMS are mainly used to assess the risk of recurrence and to select patients for adjuvant chemotherapy; notably, no consensus has been reached on the lack of utility of BCMS for selecting the type of chemotherapy to administer. Also, there are discrepancies between the recommended and current use of BCMS in clinical practice, with use in certain patient profiles for which there is no supporting evidence. Our study suggests that physician education initiatives are needed to ensure the correct use and interpretation of BCMS to, ultimately, improve management of patients with eBC.© 2023. The Author(s).